Baseline Characteristics Module
The Baseline Characteristics Module provides demographic and baseline characteristics information for participants in a clinical trial. This module includes data such as population descriptions and the types of units analyzed, helping researchers understand the baseline characteristics of study participants.
Baseline Characteristics Module path is as follows:
Study -> Results Section -> Baseline Characteristics Module
Baseline Characteristics Module
Ignite Creation Date:
2025-12-25 @ 3:44 AM
Ignite Modification Date:
2025-12-26 @ 2:30 AM
NCT ID:
NCT02876302
Population Description:
Treatment-naïve patients received a 7-day run-in window of ruxolitinib alone or ruxolitinib plus paclitaxel. The primary endpoint objective was the percent of pSTAT3-positive pre-window phase tumors that became pSTAT3-negative. (After the window phase, those who received ruxolitinib alone proceeded to neoadjuvant therapy with either ruxolitinib plus paclitaxel or paclitaxel alone for 12 weeks; those who had received ruxolitinib plus paclitaxel continued treatment for 12 weeks.
Study:
NCT02876302
Study Brief:
Results Section:
NCT02876302